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nodeficiency virus-(HIV)-1-infected patients in Taiwan in the era of combination antiretroviral
therapy (cART).
Methods: From July 2009 to March 2012, a prospective observational study was conducted to
identify the etiology of pulmonary complications in HIV-1-infected patients who sought HIV care
at a university hospital in Taiwan. A stepwise diagnostic approach was adopted, which included
radiography, serology, microbiology, bronchoscopy or video-assisted thoracoscopic surgery, and
polymerase chain reaction assays for cytomegalovirus and Pneumocystis jirovecii.of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
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TuberculosisResults: During the studyperiod,a total of 203episodesofpulmonarycomplications that occurred
in 190 patients with a mean CD4 count of 123 106 cells/L were analyzed. Thirty-eight episodes
(18.7%) occurred in patients with a CD4 count >200  106 cells/L, 71 (35.0%) between 50 and
200 106 cells/L, and 94 (46.3%)<50 106 cells/L. Pneumocystis pneumonia accounted formore
than half of the complications in patients with a CD4 count <200  106 cells/L. In patients with
a CD4 count>200 106 cells/L, the etiology of pulmonary complications was diverse, with bacte-
rial infections (47.4%) being the most common, followed by tuberculosis (15.8%) and lung edema
(13.2%). Pneumocystosis and cytomegalovirus pneumonitis were seen mostly or exclusively in
patients with a CD4 count<200 106 cells/L and were the leading causes of interstitial pneumo-
nitis. On the other hand, empyema, legionellosis, and lung edema were more commonly seen in
patients with a CD4 count >200 106 cells/L.
Conclusions: The etiology of pulmonary complications in HIV-1-infected patients was diverse and
varied with the categories of CD4 counts. Pneumocystosis remained the leading cause of pulmo-
nary complications in patients with lower CD4 counts in Taiwan in the cART era.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Pulmonary complications remain the leading cause of
morbidity and mortality of human immunodeficiency virus-
(HIV)-1-infected patients in the era of combination anti-
retroviral therapy (cART) while its spectrum is changing.1,2
For patients who are taking effective cART and antimicro-
bial prophylaxis, opportunistic infections have declined in
frequency, and prolonged survival with cART has allowed
other processes to occur, such as bronchogenic carcinoma,
chronic obstructive pulmonary disease, and pulmonary
hypertension.3e5 In contrast, for patients who have limited
access to HIV care and who are not taking cART or antimi-
crobial prophylaxis, opportunistic infections and
immunosuppression-related neoplasms continue to occur.1
CART was first introduced into Taiwan in April 1997.
Currently, all HIV-infected patients are provided free
access to inpatient or outpatient care including cART at
designated hospitals around Taiwan. The survival of HIV-
infected patients has significantly improved6e8 and inci-
dences of several opportunistic infections have declined
with introduction of cART.6,9 However, pulmonary compli-
cations that require critical care and result in substantial
mortality continue to occur in the cART era.10 With
improved survival, aging, and a high prevalence of smoking,
pulmonary complications are likely to play an increasingly
important role in morbidity and mortality in HIV-infected
patients who receive cART.4 While several retrospective
studies in Taiwan have reported on specific pulmonary
complications in HIV-infected patients,11e13 little is known
about the spectrum of pulmonary complications in this
population in the cART era. In this prospective observa-
tional study, we investigated the etiology of pulmonary
complications among HIV-infected patients who sought HIV
care at a university hospital in Taiwan.
Methods
Study population and data collection
From July 2009 to March 2012, a prospective observational
study was conducted at the National Taiwan UniversityHospital, the largest referral hospital for HIV care in
Taiwan. HIV-infected patients aged 20 years who pre-
sented with respiratory symptoms and signs and required
inpatient care were identified. After obtaining a clinical
history and physical examination, a stepwise diagnostic
approach was adopted as part of routine clinical care,
which included chest radiography, serologies, and acid-fast
staining and microbiologic cultures of clinical specimens.
For patients with interstitial pneumonitis that was
demonstrated by high-resolution computed tomography
(HRCT) of the chest, blood specimens and sputum or
bronchoalveolar lavage (BAL) specimens were obtained for
polymerase chain reaction (PCR) assays for cytomegalovirus
(CMV) and Pneumocystis jirovecii, respectively. Serologic
tests included cryptococcal antigen and aspergillus antigen
of the serum specimens,14 and pneumococcal and legion-
ella antigen of the urine specimens. Chest sonography- or
CT-guided aspiration/biopsy would be performed in
patients with tumors that were peripherally located and
bronchoscopy and/or video-assisted thoracoscopic surgery
were performed after consulting with chest medicine
specialists and chest surgeons when previous investigations
remained nondiagnostic.
A standardized case record form was used to collect the
clinical, laboratory, and histopathologic data, including
gender; age; HIV-related variables (CD4 count, plasma HIV
RNA load, and cART); smoking; baseline pulmonary and
systemic diseases; results of cultures, serological tests, PCR
assays, and pathology; clinical diagnosis; and outcomes.
Patientswere classified as ‘ever-smokers’ if they had smoked
more than 100 lifetime cigarettes. The latest CD4 count that
was obtained within 3 months of onset of the illness was
recorded for each episode. The study was approved by the
Research Ethics Committee of National Taiwan University
Hospital and informed consent was waived.
Definitions
If patients had been hospitalized more than once due to
different pulmonary complications, each hospitalization
was regarded as an independent episode. Moreover,
patients might have more than one diagnosis during each
episode. Recurrence of pre-existing diseases was excluded.
HIV-related pulmonary complications in the cART era 435Pneumocystosis was diagnosed if: (1) P. jirovecii was
identified by cytology of sputum or BAL specimen, or
histopathology of lung biopsy specimen (confirmed cases);
(2) the PCR assay for Pneumocystis 16S rRNA of sputum or
BAL specimen was positive, plus a typical clinical history
and image findings of interstitial pneumonitis (probable
cases); and (3) patients presented with a typical clinical
history and interstitial pneumonitis, for which anti-
pneumocytosis therapy was initiated (presumptive cases).
Patients were diagnosed to have CMV pneumonitis if: (1)
the lung biopsy demonstrated pneumonitis and cytopathic
effect consistent with CMV (confirmed cases); and (2) the
chest radiography revealed interstitial pneumonitis and
CMV was detected in the serum or respiratory specimens by
PCR assays with clinical response to anti-CMV treatment
with ganciclovir or foscarnet (probable cases). Bacterial
pneumonia was diagnosed when patients presented with
consistent respiratory symptoms, infiltrates by chest radi-
ography, growth of typical respiratory pathogens, or posi-
tive results of pneumococcal or legionella antigen assays of
urine specimens. In patients without microbiologic confir-
mation, bacterial pneumonia was diagnosed by the pres-
ence of respiratory symptoms, infiltrates by chest
radiography, and favorable clinical response to antibiotic
therapy. Tuberculosis (TB) was confirmed in patients with
positive cultures of sputum specimens for Mycobacterium
tuberculosis; or probable TB was diagnosed if chest radi-
ography showed pulmonary infiltrates with or without
cavitation, or miliary infiltrates, in addition to clinical
response to anti-TB therapy. Nontuberculous mycobacterial
infection was diagnosed if patients had positive culture
results for nontuberculous mycobacteria (NTM) from at
least two separate expectorated sputum specimens or at
least one BAL specimen, with exclusion of other diagnoses.
Diagnosis of crypotococcosis, aspergillosis, or penicillosis of
the lung was made when patients presented with pulmo-
nary infiltrates by chest radiography plus positive serologic,
mycobiologic, or histopathologic studies of clinical speci-
mens. Diagnoses of malignant diseases were based on
histpathologic examinations of tissue biopsies. Pulmonary
hypertension was confirmed by echocardiography, while
pulmonary embolism by CT of the lungs. Lung edema was
diagnosed when patients presented with a consistent clin-
ical history plus chest radiography.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 17.0; SPSS Inc., Chicago, IL, USA). The c2 test or
Fisher’s exact test was used for categorical variables, and
the one-way analysis of variance for continuous data. All
tests were two-tailed and differences were considered
statistically significant at p < 0.05.
Results
During the study period, 218 episodes that occurred in 197
HIV-infected adult patients were identified. Thirteen
episodes were excluded due to non-pulmonary diseases
(five) or recurrent episodes (eight), and two others were
excluded because of lacking CD4 count data in last threemonths. A total of 203 episodes in 190 patients were
included for analysis.
The baseline characteristics of all patients are shown in
Table 1. The mean CD4 count was 123  106 cells/L. Ninety-
four episodes (46.3%) occurred in patients with a CD4 count
<50  106 cells/L, 71 (35.0%) between 50 to
200  106 cells/L, and 38 (18.7%) >200  106 cells/L; the
mean age of these three groups was 38, 39, and 49 years,
respectively (p < 0.001). Almost all (96.6%) of the patients
were male, with homosexual or bisexual contact as the
most common route for HIV transmission. While 125
patients were previously diagnosed as having HIV infection,
only 51 (40.8%) were receiving cART for >30 days before
presentation, among who 40 (78.4%) had achieved
successful viral suppression (defined as plasma HIV RNA
level <400 copies/mL). Two-fifths (41.4%) of the patients
were ever-smokers, and 10.8% had pre-existing pulmonary
diseases. Nearly half of the patients had been healthy
before without any pulmonary or systemic diseases.
The etiologies of pulmonary complications are shown in
Table 2. In 38 episodes,more thanoneetiologywas identified
(two etiologies in 34 episodes, three in two, and four in two).
P jirovecii pneumonia was the most common etiology, which
accounted formore thanhalf of the complications in patients
with a CD4 count <200  106 cells/L. Bacterial infections
were the second common cause of pulmonary complications
(18.7% of all cases), and the proportion was higher among
patients with a CD4 count>200 106 cells/L (p< 0.001). Of
note, the proportion of pneumococcal pneumonia was
similar in patients with different CD4 count categories. On
the other hand, legionellosis and empyema were more
commonly seen in patients with a CD4 count
>200  106 cells/L compared with those with a CD4 count
<200  106 cells/L (pZ 0.03 and 0.001, respectively). CMV
pneumonitis was diagnosed in 26 episodes (12.8%), for which
seven (26.9%) were confirmed by histopathology of lung
biopsy specimens. CMV pneumonitis were seen exclusively in
patients with a CD4 count <200  106 cells/L (p Z 0.01).
Pulmonary TB was diagnosed in 8.4% of the patients, which
accounted for a significantly higher proportion among
patientswith aCD4 count>50 106 cells/L: 1.1%, 14.1%, and
15.8% of the cases in patientswith a CD4 cell count<50, 50 to
200, and>200 106 cells/L, respectively (CD4 count<50 vs.
50 to 200, pZ 0.001; CD4 count <50 vs. >200, pZ 0.002).
Other less common infectious etiology of pulmonary
complications included M avium complex (MAC) infection,
NTM infection other than MAC (both 3.0%), cryptococcosis
(2.5%), aspergillosis, and penicilliosis marneffei (both 1.5%).
Ten patients (4.9%) were diagnosed to have malignancies
involving the lungs, which included non-Hodgkin’s
lymphoma (six), Kaposi’s sarcoma (one), multicentric Cas-
tleman’s disease (one), nonesmall-cell lung cancer (one),
and metastatic squamous cell carcinoma of unknown
primary origin (one). Lung edema resulting from congestive
heart failure or impaired renal function was diagnosed in
3.4% of the cases, which was almost exclusively seen in
patients with a CD4 count >200  106 cells/L (p Z 0.003).
The etiology of pulmonary complication remained uniden-
tified in 7.9% of the cases.
Fig. 1 demonstrates the relationship between CD4
counts and pulmonary complications with a proportion
2.5% of all episodes. Pneumocystosis, CMV pneumonitis,
Table 1 Baseline characteristics of 190 HIV-infected patients with 203 episodes of pulmonary complications
Variables All episodes Episodes occurring in patients with different CD4 count
categories
p
<50  106 cells/L 50-200  106 cells/L >200  106 cells/L
Number of episodes, n (%) 203 94 (46.3) 71 (35.0) 38 (18.7)
Age, mean (SD), years, 40 (12) 38 (9) 39 (9) 49 (16) <0.001
Male gender, n (%) 196 (96.6) 90 (95.7) 70 (98.6) 36 (94.7) 0.48
Risk behaviors for HIV transmission, n (%)
Homosexual/bisexual 151 (74.4) 73 (77.7) 59 (83.1) 19 (50.0)
IDU 10 (4.9) 0 4 (5.6) 6 (15.8)
Both homosexual and IDU 3 (1.5) 1 (1.1) 2 (2.8) 0
Others or unknown 39 (19.2) 20 (21.3) 6 (15.8) 13 (34.2)
Previously diagnosed with
HIV infection, n (%)
125 (61.6) 45 (47.9) 44 (62.0) 36 (94.7) <0.001
Latest CD4 cell count,  106 cells/L
mean (SD) 123 (175) 20 (14) 94 (36) 434 (190) <0.001




Latest plasma HIV RNA load, mean (SD),
log10 copies/ml,
4.4 (1.6) 5.1 (1.0) 4.7 (1.3) 2.4 (1.4) <0.001
Patients with data, n 189 87 65 37
<400 copies/ml, n (%) 40 (21.2) 3 (3.4) 8 (12.3) 29 (78.4)
On cART 51 (25.1) 7 (7.4) 13 (18.3) 31 (81.6)
On TMP/SMX among patients with a
CD4 count <200  106 cells/L, n (%)
22 (13.3) 13 (13.8) 9 (12.7) d
Ever-smoker, n (%) 84 (41.4) 37 (39.4) 29 (40.8) 18 (47.4) 0.70
Pulmonary disease at baseline, n (%)
COPD 4 (2.0) 0 1 (1.4) 3 (7.9) 0.01
Asthma 4 (2.0) 2 (2.1) 2 (2.8) 0 0.83
Bronchiectasis 2 (1.0) 2 (2.1) 0 0 0.67
Tuberculosis 9 (4.4) 4 (4.3) 2 (2.8) 3 (7.9) 0.44
Non-tuberculous mycobacteriosis 4 (2.0) 2 (2.1) 1 (1.4) 1 (2.6) >0.99
Systemic diseases at baseline, n (%)
Diabetes mellitus 10 (4.9) 1 (1.1) 1 (1.4) 8 (21.1) <0.001
Hypertension 10 (4.9) 2 (2.1) 2 (2.8) 6 (15.8) 0.007
Cardiovascular diseases 8 (3.9) 0 2 (2.8) 6 (15.8) <0.001
Chronic HBV infection 42 (20.7) 19 (20.2) 18 (25.4) 5 (13.2) 0.32
Chronic HCV infection 7 (3.4) 1 (1.1) 1 (1.4) 5 (13.2) 0.003
Renal disease 4 (2.0) 1 (1.1) 0 3 (7.9) 0.02
Solid-organ malignancy 5 (2.5) 0 3 (4.2) 2 (5.3) 0.06
Hematological malignancy 6 (3.0) 2 (2.1) 2 (2.8) 2 (5.3) 0.58
Hematological disease 5 (2.5) 2 (2.1) 1 (1.4) 2 (5.3) 0.50
Autoimmune disease 2 (1.0) 2 (2.1) 0 0 0.67
None 101 (49.8) 51 (54.3) 37 (52.1) 13 (34.2) 0.10
cARTZ combination antiretroviral therapy; COPDZ chronic obstructive pulmonary disease; HBVZ hepatitis B virus; HCVZ hepatitis C
virus; IDU Z injecting drug user; SD Z standard deviation; TMP/SMX Z trimethoprim/sulfamethoxazole.
P values marked in bold if <0.05.
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lymphoma occurred mostly or exclusively in patients with
a CD4 count <200  106 cells/L, whereas bacterial infec-
tions, pulmonary TB, and lung edema could be seen in
patients with higher CD4 cell counts.
HRCT of the chest was performed in 73.4% of the cases
(nZ 149), and the predominantly interstitial patternwas themost common radiographic finding that was seen in 65.8% of
the cases (n Z 98). In patients presenting with interstitial
pneumonitis, the majority (92.9%) had pneumocystosis only
(65 cases) or pneumocystosis with other concomitant etiol-
ogies (26 cases; Table 3). The etiologies of the remaining
cases includedCMVpneumonitis (two) and lung edema (one).
Four patients did not have a definite diagnosis.
Table 2 Etiology and clinical outcome of 190 HIV-infected patients with 203 episodes of pulmonary complications
Etiology, n (%) Total episodes
n Z 203
Episodes occurring in patients with different categories of CD4
counts
p
<50  106 cells/L
(n Z 94)
50-200  106 cells/L
(n Z 71)
>200  106 cells/L
(n Z 38)
Pneumocystis pneumonia 106 (52.2) 65 (69.1) 39 (54.9) 2 (5.3) <0.001
Bacterial infection 38 (18.7) 10 (10.6) 10 (14.1) 18 (47.4) <0.001
(1) Bacterial pneumonia 32 (15.8) 9 (9.6) 10 (14.1) 13 (34.2) 0.002
Pneumococcal infection 9 (4.4) 3 (3.2) 3 (4.2) 3 (7.9) 0.49
Legionellosis 2 (1.0) 0 0 2 (5.3) 0.03
Nocardiosis 2 (1.0) 2 (2.1) 0 0 0.27
(2) Empyema 6 (3.0) 1 (1.1) 0 5 (13.2) 0.001
Cytomegalovirus pneumonitis 26 (12.8) 18 (19.1) 8 (11.3) 0 0.01
Tuberculosis 17 (8.4) 1 (1.1) 10 (14.1) 6 (15.8) 0.002
MAC infection 6 (3.0) 3 (3.2) 3 (4.2) 0 0.66
Other NTM infection 6 (3.0) 4 (4.3) 1 (1.4) 1 (2.6) 0.75
Cryptococcosis 5 (2.5) 0 4 (5.6) 1 (2.6) 0.04
Aspergillosis 3 (1.5) 3 (3.2) 0 0 0.30
Penicillium marneffei pneumonia 3 (1.5) 3 (3.2) 0 0 0.30
Non-Hodgkin’s lymphoma 6 (3.0) 5 (5.3) 1 (1.4) 0 0.29
Kaposi’s sarcoma 1 (0.5) 1 (1.1) 0 0 >0.99
Multicentric Castleman’s disease 1 (0.5) 0 0 1 (2.6) 0.19
Lung cancer 1 (0.5) 0 0 1 (2.6) 0.19
Metastatic cancer 1 (0.5) 0 0 1 (2.6) 0.19
Pulmonary hypertension 2 (1.0) 0 1 (1.4) 1 (2.6) 0.29
Pulmonary embolism 1 (0.5) 0 1 (1.4) 0 0.54
Lung edema 7 (3.4) 1 (1.1) 1 (1.4) 5 (13.2) 0.003
Inconclusive 16 (7.9) 8 (8.5) 4 (5.6) 4 (10.5) 0.63
Outcome, n (%)
Respiratory failure 40 (19.7) 27 (28.7) 8 (11.3) 5 (13.2) 0.01
ICU admission 42 (20.7) 25 (26.6) 10 (14.1) 7 (18.4) 0.14
In-hospital mortality 31 (15.3) 22 (23.4) 6 (8.5) 3 (7.9) 0.01
ICU Z intensive care unit; MAC Z Mycobacterium avium complex; NTM infection Z non-tuberculous mycobacterial infection.
P values marked in bold if <0.05.
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patients developed respiratory failure and 20.7% had been
admitted to the intensive care units. The in-hospital
mortality rate was 15.3%. Patients with a CD4 count
<50  106 cells/L were more likely to develop respiratory
failure and had a higher in-hospital mortality rate than
those with a CD4 count >50  106 cells/L (pZ 0.01 for both
comparisons).
Of the 106 patients who developed PCP in the cART era,
54.7% were newly diagnosed as having HIV infection; 19.8%
had never received cART after HIV infection was diagnosed;
and 21.7% had interrupted cART due to various reasons. The
latest CD4 counts of the patients who never received cART
were all <200  106 cells/L, except one who had a CD4
count of 228  106 cells/L. Only four patients (3.7%) were
receiving cART when PCP developed: one patient with
multi-drug resistant HIV-1 infection after experiencing
multiple failures to cART who discontinued trimethroprim-
sulfamethoxazole 4 months prior to this episode due to
impaired renal function; the other three patients who had
not been prescribed prophylaxis for pneumocystosis
and were receiving cART with successful viral suppression
had latest CD4 counts <200  106 cells/L (34, 133, and170  106 cells/L, respectively). Of note, two of the three
patients had received chemotherapy containing cortico-
steroids for non-Hodgkin’s lymphoma within one month
prior to the episodes.
Discussion
In this observational study, we found that P jirovecii
pneumonia remained the most common cause of pulmonary
complications in HIV-infected Taiwanese patients in the era
of cART, especially those with a CD4 count
<200  106 cells/L. Bacterial infections and tuberculosis
were the second and fourth common etiology, which
accounted for a larger proportion among patients with
higher CD4 counts. CMV pneumonitis was the third common
etiology and occurred exclusively in patients with a CD4
count <200  106 cells/L.
The incidence of pneumocystosis has declined markedly
after the introduction of trimethoprim/sulfamethoxazole
prophylaxis and cART6,15,16; nevertheless, pneumocystosis
continues to be a common presenting opportunistic illness
in HIV-infected individuals who are unaware of their HIV
infection, those who fail to access HIV care, and those who
Figure 1. Relationship between CD4 cell counts and the
types of pulmonary complications. Boxplot of the median (line
inside the box), first quartile (bottom of the box), third quar-
tile (top of the box), minimum and maximum except outliers
(lower and upper whiskers) of CD4 cell counts for pulmonary
complications. Asterisks and dots are outliers >3.0 and 1.5
interquartile range. The case number for each etiology is
shown in the bracket. PCP Z Pneumocystis pneumonia;
Bact.Z bacterial infection; CMVZ cytomegalovirus infection;
TB Z tuberculosis; MAC Z Mycobacterium avium complex
infection; NTM Z non-tuberculous mycobacterial infection;
Cryp. Z cryptococcosis; NHL Z non-Hodgkin’s lymphoma;
L.E. Z lung edema.
438 K.-Y. Lee et al.fail to adhere to antiretroviral therapy or antimicrobial
prophylaxis.15 In our study, pneumocystosis remained the
most common etiology of pulmonary complications in HIV-
infected Taiwanese patients, and the aforementionedTable 3 Etiology of pulmonary complications with an
interstitial pattern on high-resolution computed tomog-
raphy of the chest
Etiology, n (%) Total episodes
n Z 98
Pneumocystis pneumonia 91 (92.9)
Isolated 65 (66.3)
With concomitant etiology 26 (26.5)
CMV pneumonitis 15 (15.3)
CMV pneumonitis and Penicillium
marneffei pneumonia
1 (1.0)




Bacterial infection 5 (5.1)
NTM infection 2 (2.0)
Cryptococcosis 1 (1.0)
CMV pneumonitis 20 (20.4)
Isolated 2 (2.0)
With concomitant etiologies 18 (18.4)
Lung edema 1 (1.0)
Inconclusive 4 (4.1)
CMV Z cytomegalovirus; NTM infection Z nontuberculous
mycobacterial infection.reasons can be cited for the majority of our patients who
developed this complication. More emphasis is needed in
Taiwan to increase awareness of HIV infection among
persons at risk and health care providers,17 facilitate early
diagnosis of HIV infection, retain HIV-infected patients in
care, and provide timely and appropriate antimicrobial
prophylaxis and cART for those who meet the criteria.
In our study, few patients developed pneumocystosis
while receiving cARTwith successful viral suppression. They
were not prescribed with trimethoprim/sulfamethoxazole
for prophylaxis while their CD4 counts had not increased to
>200  106 cells/L. There is an increasing number of
studies suggesting that discontinuation of prophylaxis for
pneumocystosis may be safe in patients with CD4 counts of
101 to 200  106 cells/L and viral suppression.18,19
However, this strategy should warrant cautious judgment
when applied to all patients, especially those who have
additional risk factors for pneumocystosis, such as lym-
phoproliferative malignancies and use of corticosteroids.20
Bacterial pneumonia occurs more frequently in HIV-
infected patients, and the incidence increases as the CD4
count decreases.21,22 Despite the overall reduction in the
incidence of bacterial pneumonia after the introduction of
cART, it remains a common pulmonary complication in HIV-
infected persons,23 which was also seen in the study. Of
note, pneumococcal pneumonia could occur at any stage of
HIV infection,24 and HIV-infected patients have a higher risk
for invasive pneumococcal diseases than the general pop-
ulation even after the introduction of cART.25,26 As a result,
other preventive interventions for pneumococcal disease
such as pneumococcal vaccination are important.
The incidence of CMV end-organ diseases such as reti-
nitis and colitis was >20%/year in HIV-infected patients
with a CD4 count <100  106 cells/L.27,28 However, CMV as
a pulmonary pathogen has been considered uncommon;
only 0.24% to 8% of HIV-infected patients received a diag-
nosis of CMV pneumonitis in previous studies.29,30 The
definite diagnosis of CMV pneumonitis remains controver-
sial. The presence of CMV in BAL specimens by culture or
cytology is neither a sensitive nor a specific test for CMV
pneumonitis.31e34 Lung biopsy is likely to be more specific
for CMV pneumonitis, but the procedure is invasive and may
be insensitive due to the patchy nature of the disease. In
our study, the definition of CMV pneumonitis was similar to
that of the AIDS Clinical Trials Group (ACTG) Protocol 360
Study,30 but only patients who responded to anti-CMV
treatment were defined as probable cases. CMV pneumo-
nitis occurred in almost 20% of the patients with a CD4
count <50  106 cells/L, and the actual incidence could be
higher because severely immunocompromised patients with
CMV pneumonitis might not respond to therapy or their
critical illness might preclude them from invasive diag-
nostic procedures.
TB was the fourth common etiology of pulmonary
complications, and accounted for 8.4% of the cases in this
study. TB can occur at any stage of HIV infection. 35,36
Interestingly, TB accounted for a significantly lower propor-
tion among patients with a CD4 count<50 106 cells/L than
thosewithaCD4count>50106 cells/L in our study (1.1% vs.
14.7%). In patients with low CD4 counts, TB tends to become
disseminated and have atypical or minimal changes on chest
radiography when the patients present for clinical care.34,35
HIV-related pulmonary complications in the cART era 439As a result, some of the patients with disseminated TB may
not be included in this study, although in our stepwise diag-
nostic approach, acid-fast smears and TB cultures of respi-
ratory tract specimens were routinely performed in patients
with fever and respiratory symptoms. The lower prevalence
of TB may also be because of a significantly higher case
number of interstitial pneumonitis and a higher mortality
rate in the patients with CD4 <50  106 cells/L. The higher
mortality may preclude us from detecting concomitant TB at
presentation in this subgroup.
In patients with a low CD4 count, other opportunistic
infections and neoplasms such as infections due to NTM,
aspergillosis, penicilliosis, cryptococcosis, non-Hodgkin’s
lymphoma, and Kaposi’s sarcoma were also seen in our
study, although less frequently. On the other hand, some
rare diseases including pulmonary hypertension, multi-
centric Castleman’s disease, and bronchogenic cancer
occurred in patients with a higher CD4 cell count. These
disease entities may warrant clinicians’ attention since
their pathogenesis is associated with HIV infection and/or
the incidences are higher in HIV-infected patients than in
uninfected people.37e39
Our study has several limitations. First, this is a single
center study conducted at a referral hospital in Taiwan. As
a result, the disease severity of the patients may be
higher than the HIV population in general in Taiwan.
Second, the definite diagnosis of certain pulmonary
diseases, such as CMV pneumonitis and neoplasms, mainly
relied on histopathology. Therefore, under-diagnosis may
have occurred. Last, limited by the sample size, we were
not able to analyze the association between the etiologies
of pulmonary complications and many other factors
such as plasma HIV RNA level, cART status, virological
and immunological responses to cART, and other co-
morbidities.
In conclusion, pneumocystosis remained the most
common cause in HIV-1-infected patients with lower CD4
cell counts in the cART era in Taiwan. The etiology of
pulmonary complications was different between patients
with CD4 counts <200  106 cells/L and those with CD4
>200  106 cells/L.Conflicts of interest
All authors declare that they have no conflicts of interest
relevant to this article.References
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